Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3427 USD | 0.00% | -2.48% | -43.82% |
03-21 | Dermata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
01-05 | Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 2.28M 182M |
---|---|---|---|---|---|
Net income 2024 * | -12M -956M | Net income 2025 * | -14M -1.12B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.25
x | P/E ratio 2025 * |
-0.52
x | Employees | 8 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.15% |
1 day | -1.96% | ||
1 week | -2.48% | ||
Current month | -16.58% | ||
1 month | -17.82% | ||
3 months | -28.90% | ||
6 months | -40.91% | ||
Current year | -43.82% |
Managers | Title | Age | Since |
---|---|---|---|
Gerry Proehl
CEO | Chief Executive Officer | 65 | 07/12/14 |
David Hale
FOU | Founder | 75 | 07/12/14 |
Kyri van Hoose
DFI | Director of Finance/CFO | - | 31/08/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Hale
FOU | Founder | 75 | 07/12/14 |
Gerry Proehl
CEO | Chief Executive Officer | 65 | 07/12/14 |
Wendell Wierenga
BRD | Director/Board Member | 76 | 19/09/16 |
Date | Price | Change | Volume |
---|---|---|---|
29/04/24 | 0.3427 | 0.00% | 54 296 |
26/04/24 | 0.3427 | +0.76% | 16,675 |
25/04/24 | 0.3401 | -4.68% | 9,619 |
24/04/24 | 0.3568 | +5.03% | 18,879 |
23/04/24 | 0.3397 | -3.33% | 23,509 |
Delayed Quote Nasdaq, April 29, 2024 at 04:43 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-43.82% | 2.28M | |
-2.70% | 103B | |
+1.69% | 95.28B | |
+1.46% | 22.15B | |
-15.97% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.00% | 16.05B | |
+4.59% | 13.68B | |
+35.27% | 12.17B |
- Stock Market
- Equities
- DRMA Stock